CN1898266B - 使用羟磷灰石层析除去高分子量聚集体 - Google Patents

使用羟磷灰石层析除去高分子量聚集体 Download PDF

Info

Publication number
CN1898266B
CN1898266B CN2004800387536A CN200480038753A CN1898266B CN 1898266 B CN1898266 B CN 1898266B CN 2004800387536 A CN2004800387536 A CN 2004800387536A CN 200480038753 A CN200480038753 A CN 200480038753A CN 1898266 B CN1898266 B CN 1898266B
Authority
CN
China
Prior art keywords
antibody
hydroxyapatite
buffer
protein
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800387536A
Other languages
English (en)
Chinese (zh)
Other versions
CN1898266A (zh
Inventor
S·孙
C·加洛
B·凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to CN201110221442.5A priority Critical patent/CN102276717B/zh
Publication of CN1898266A publication Critical patent/CN1898266A/zh
Application granted granted Critical
Publication of CN1898266B publication Critical patent/CN1898266B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/04—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
    • B01J20/048—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium containing phosphorus, e.g. phosphates, apatites, hydroxyapatites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/282—Porous sorbents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CN2004800387536A 2003-10-27 2004-10-06 使用羟磷灰石层析除去高分子量聚集体 Expired - Lifetime CN1898266B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110221442.5A CN102276717B (zh) 2003-10-27 2004-10-06 使用羟磷灰石层析除去高分子量聚集体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51401803P 2003-10-27 2003-10-27
US60/514,018 2003-10-27
US52333503P 2003-11-20 2003-11-20
US60/523,335 2003-11-20
PCT/US2004/032883 WO2005044856A2 (en) 2003-10-27 2004-10-06 Removal of high molecular weight aggregates using hydroxyapatite chromatography

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110221442.5A Division CN102276717B (zh) 2003-10-27 2004-10-06 使用羟磷灰石层析除去高分子量聚集体

Publications (2)

Publication Number Publication Date
CN1898266A CN1898266A (zh) 2007-01-17
CN1898266B true CN1898266B (zh) 2011-09-21

Family

ID=34576743

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800387536A Expired - Lifetime CN1898266B (zh) 2003-10-27 2004-10-06 使用羟磷灰石层析除去高分子量聚集体
CN201110221442.5A Expired - Lifetime CN102276717B (zh) 2003-10-27 2004-10-06 使用羟磷灰石层析除去高分子量聚集体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201110221442.5A Expired - Lifetime CN102276717B (zh) 2003-10-27 2004-10-06 使用羟磷灰石层析除去高分子量聚集体

Country Status (19)

Country Link
US (2) US9469672B2 (enExample)
EP (2) EP1678208B1 (enExample)
JP (2) JP5004586B2 (enExample)
KR (2) KR101221862B1 (enExample)
CN (2) CN1898266B (enExample)
AU (1) AU2004286938B2 (enExample)
BR (2) BRPI0415887B1 (enExample)
CA (1) CA2543193C (enExample)
CO (1) CO5690649A2 (enExample)
DK (2) DK1678208T3 (enExample)
EC (1) ECSP066583A (enExample)
ES (2) ES2530446T3 (enExample)
IL (1) IL175229A (enExample)
MX (1) MXPA06004472A (enExample)
NZ (1) NZ547315A (enExample)
PL (2) PL2336172T3 (enExample)
PT (2) PT1678208E (enExample)
RU (2) RU2409591C2 (enExample)
WO (1) WO2005044856A2 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
KR101221862B1 (ko) * 2003-10-27 2013-01-14 와이어쓰 엘엘씨 하이드록시아파타이트 크로마토그래피를 사용한 고분자량응집체의 제거
ES2797480T3 (es) * 2005-03-11 2020-12-02 Wyeth Llc Un procedimiento de cromatografía de reparto débil
CN101213211A (zh) * 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
CN101378782A (zh) * 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
US8088833B2 (en) 2006-04-25 2012-01-03 Tosoh Corporation Method for purifying an IgG monomer
EP2069387A4 (en) * 2006-06-14 2011-02-02 Glaxosmithkline Llc METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC
CA2661748C (en) * 2006-08-28 2016-02-09 Alex Eon-Duval Process for the purification of fc-containing proteins
US20100267932A1 (en) * 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins
WO2008031020A2 (en) * 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US7999085B2 (en) * 2007-01-09 2011-08-16 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
JP2010516744A (ja) * 2007-01-26 2010-05-20 メルク セローノ ソシエテ アノニム 油体技術を用いたＦｃ−融合タンパク質の精製
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2719705B1 (en) * 2007-10-26 2020-07-29 Asahi Kasei Kabushiki Kaisha Method for purifying protein
JP5999899B2 (ja) * 2008-04-08 2016-09-28 バイオ−ラッド ラボラトリーズ インコーポレーティッド 抗体のクロマトグラフィー精製法
DK2848625T3 (da) † 2008-08-14 2019-10-07 Genentech Inc Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CN102272154A (zh) * 2008-10-29 2011-12-07 惠氏有限责任公司 单域抗原结合性分子的纯化方法
ES2699434T3 (es) * 2008-10-31 2019-02-11 Wyeth Llc Purificación de proteínas ácidas utilizando cromatografía de hidroxiapatita cerámica
AU2010260476A1 (en) * 2009-03-11 2011-10-13 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
US8481694B2 (en) 2009-04-29 2013-07-09 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
WO2011001963A1 (ja) 2009-07-03 2011-01-06 旭化成ケミカルズ株式会社 多孔質基材に固定されたグラフト鎖に結合しているアミノ基及びアルキル基を有する多孔膜を用いた抗体の精製方法
RU2603055C2 (ru) 2009-10-20 2016-11-20 Эббви Инк Выделение и очистка антител против il-13 с применением аффинной хроматографии с белком а
CA2784278C (en) 2009-12-18 2019-02-26 Novartis Ag Wash solution and method for affinity chromatography
US20130116413A1 (en) * 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
JP5773454B2 (ja) * 2010-01-15 2015-09-02 バイオ−ラッド ラボラトリーズ インコーポレーティッド アパタイトの表面中和方法
JP5737817B2 (ja) * 2010-04-14 2015-06-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 免疫グロブリン凝集体の除去
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
WO2011156073A1 (en) * 2010-06-08 2011-12-15 Millipore Corporation Removal of protein aggregates from biopharmaceutical preparations using calcium phosphate salts
US8895707B2 (en) * 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
KR20130131352A (ko) * 2010-11-01 2013-12-03 디에스엠 아이피 어셋츠 비.브이. 단일 유닛 이온 교환 크로마토그래피 항체 정제
EP2670704B1 (en) 2011-02-02 2018-12-12 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
CN103717284B (zh) * 2011-06-08 2016-02-24 新加坡科技研究局 通过约束共水合色谱纯化生物制品
MX2013014615A (es) * 2011-06-16 2014-02-17 Dsm Ip Assets Bv Purificacion de anticuerpos por cromatografia de unidad unica.
SG10201701224UA (en) 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
WO2013180933A1 (en) 2012-05-30 2013-12-05 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
WO2014003142A1 (ja) * 2012-06-27 2014-01-03 旭化成メディカル株式会社 抗体
JP2014105180A (ja) * 2012-11-27 2014-06-09 Hoya Corp モノマー化方法
CN107693781B (zh) 2013-03-13 2021-11-09 巴扎德制药公司 用于眼部递送的嵌合细胞因子制剂
HK1222871A1 (zh) * 2013-05-13 2017-07-14 Medimmune, Llc 具有最小单体分离的重组多克隆抗体多聚体的分离
KR20160029840A (ko) 2013-07-05 2016-03-15 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 친화성 크로마토그래피 매트릭스
EP3019262A1 (en) 2013-07-12 2016-05-18 Merck Patent GmbH Removal of fragments from a sample containing a target protein using activated carbon
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
JP6326499B2 (ja) 2013-12-12 2018-05-16 イー・エム・デイー・ミリポア・コーポレイシヨン アクリルアミド含有フィルターを使用したタンパク質分離
IL296754A (en) * 2013-12-27 2022-11-01 Chugai Pharmaceutical Co Ltd A method for isolating an antibody with a low isoelectric point
EP3157863B1 (en) 2014-06-23 2023-06-21 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
WO2015200282A1 (en) 2014-06-23 2015-12-30 Bio-Rad Laboratories, Inc. Apatite pretreatment
EP3233230B1 (en) 2014-12-15 2024-06-12 Merck Patent GmbH Target molecule capture from crude solutions
MX395730B (es) 2015-03-13 2025-03-25 Bristol Myers Squibb Co Uso de lavados alcalinos durante la cromatografia para remover impurezas.
US11661438B2 (en) 2015-12-21 2023-05-30 Pfizer, Inc. Purification of antibody drug conjugates using a sodium phosphate gradient
US11919924B1 (en) * 2016-03-15 2024-03-05 Fresenius Kabi Deutschland Gmbh Methods of purifying and producing an adalimumab antibody
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
CN106977591B (zh) * 2017-05-04 2020-05-05 广州康盛生物科技股份有限公司 一种分离纯化重组葡萄球菌蛋白a的方法
EP3672981A4 (en) 2017-08-22 2021-09-15 Biogen MA Inc. PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT
WO2019116096A1 (en) * 2017-12-15 2019-06-20 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of fc fragments
CA3034795A1 (en) * 2018-02-27 2019-08-27 Pfizer Inc. Antibody purification
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
US20210024573A1 (en) 2018-04-03 2021-01-28 Merck Patent Gmbh Cex chromatography media and low salt elution of target proteins from biopharmaceutical feeds
JP6951051B2 (ja) * 2018-05-24 2021-10-20 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 吸着剤の生産方法
JP6704074B2 (ja) * 2019-02-04 2020-06-03 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
WO2021099536A1 (en) 2019-11-22 2021-05-27 Morphosys Ag Method to increase antibody yield during ion exchange chromatography
JP2020099909A (ja) * 2020-03-17 2020-07-02 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 処理方法、生産方法およびハイドロキシアパタイト充填剤
MX2022012278A (es) 2020-03-30 2022-10-27 Ablynx Nv Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes.
WO2021220251A1 (en) * 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US523335A (en) 1894-07-24 Air-bolt for flour-mills
US419964A (en) 1890-01-21 Transom-lifter
US428894A (en) 1890-05-27 Process of making tool-handles
US514018A (en) 1894-02-06 Edward j
US4745183A (en) * 1984-02-21 1988-05-17 Bio-Rad Laboratories, Inc. Use of hydroxylapatite for the analysis and preparation of purified monoclonal antibodies
JPH03291300A (ja) * 1989-12-28 1991-12-20 Mitsui Toatsu Chem Inc ポリクローナル抗体の分離方法
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MXPA04006053A (es) 2001-12-21 2005-03-31 Immunex Corp Metodos para purificacion de proteina.
CA2516518A1 (en) 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
KR101221862B1 (ko) * 2003-10-27 2013-01-14 와이어쓰 엘엘씨 하이드록시아파타이트 크로마토그래피를 사용한 고분자량응집체의 제거

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GIOVANNINI ROBERTO ET AL.isolation of a recombinant antibody from cellculturesupernatant :continuous annular versus batchandexpanded-bed chromatography.BIOTECHNOLOGY AND BIOENGINEERING73 6.2001,73(6),第524页右栏第二段-第525页右栏第一段.
GIOVANNINI ROBERTO ET AL.isolation of a recombinant antibody from cellculturesupernatant :continuous annular versus batchandexpanded-bed chromatography.BIOTECHNOLOGY AND BIOENGINEERING73 6.2001,73(6),第524页右栏第二段-第525页右栏第一段. *
严自助.羟磷灰石纯化单克隆抗体.上海免疫学杂质9 6.1989,9(6),第368-369页.
严自助.羟磷灰石纯化单克隆抗体.上海免疫学杂质9 6.1989,9(6),第368-369页. *
邹岳奇等.国产羟基磷灰石纯化单克隆抗体的探讨.生物化学与生物物理进展18 2.1991,18(2),第164-165页.
邹岳奇等.国产羟基磷灰石纯化单克隆抗体的探讨.生物化学与生物物理进展18 2.1991,18(2),第164-165页. *

Also Published As

Publication number Publication date
RU2010139827A (ru) 2012-03-27
CA2543193A1 (en) 2005-05-19
KR20120003027A (ko) 2012-01-09
IL175229A0 (en) 2006-09-05
BRPI0415887B1 (pt) 2021-01-26
AU2004286938A1 (en) 2005-05-19
EP2336172B1 (en) 2014-12-10
RU2006113695A (ru) 2007-12-10
WO2005044856A2 (en) 2005-05-19
MXPA06004472A (es) 2006-06-20
JP5490156B2 (ja) 2014-05-14
EP1678208A2 (en) 2006-07-12
DK2336172T3 (en) 2015-01-26
US20050107594A1 (en) 2005-05-19
CN102276717A (zh) 2011-12-14
EP2336172A1 (en) 2011-06-22
PT1678208E (pt) 2013-07-10
ES2530446T3 (es) 2015-03-02
PT2336172E (pt) 2015-02-20
US9822143B2 (en) 2017-11-21
ES2418830T3 (es) 2013-08-16
EP1678208B1 (en) 2013-05-15
ECSP066583A (es) 2006-10-17
IL175229A (en) 2013-08-29
CN1898266A (zh) 2007-01-17
KR20060120163A (ko) 2006-11-24
WO2005044856A3 (en) 2005-06-23
CO5690649A2 (es) 2006-10-31
BR122020007658B1 (pt) 2021-07-27
US9469672B2 (en) 2016-10-18
AU2004286938B2 (en) 2011-06-30
US20130197198A1 (en) 2013-08-01
DK1678208T3 (da) 2013-07-08
PL2336172T3 (pl) 2015-04-30
CN102276717B (zh) 2015-09-09
CA2543193C (en) 2015-08-11
RU2409591C2 (ru) 2011-01-20
BRPI0415887A (pt) 2007-01-09
NZ547315A (enExample) 2008-07-31
JP2012111769A (ja) 2012-06-14
KR101321876B1 (ko) 2013-10-28
KR101221862B1 (ko) 2013-01-14
PL1678208T3 (pl) 2013-09-30
JP5004586B2 (ja) 2012-08-22
JP2007532477A (ja) 2007-11-15
RU2573910C2 (ru) 2016-01-27

Similar Documents

Publication Publication Date Title
CN1898266B (zh) 使用羟磷灰石层析除去高分子量聚集体
KR101921552B1 (ko) 사전 세정 단계를 이용하는 면역글로불린 정제
KR101482791B1 (ko) 약한 분배성 크로마토그래피법
CN102977182B (zh) 在蛋白质纯化过程中降低样品中的一种或多种杂质水平的方法
JP5064225B2 (ja) 抗体精製法
US10189891B2 (en) Affinity chromatography matrix
JP2010517942A (ja) 水溶性の非イオン性有機高分子の存在下での混合モードクロマトグラフィーによる抗体の能力の増大および精製方法
CN102272145A (zh) 亲和色谱基质
CN101043947B (zh) 一种纯化抗体的方法
CN113747960A (zh) 用于再生色谱树脂的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20110921

CX01 Expiry of patent term